Shandong Oriental Ocean unit gets medical device registration amid net loss

Shandong Oriental Ocean Sci-Tech's third-quarter 2025 report shows a net loss of 105,403,075.92 yuan attributable to shareholders for the first nine months of 2025. This 51.43% decrease year-on-year is primarily due to a decline in gross profit margin from sea cucumber, testing, and reagent kit sales.

Meanwhile, the company's subsidiary, Aiwei Biological Technology, received a medical device registration certificate for its NT-proBNP assay kit. This newly approved product is valid from October 29, 2025, to October 28, 2030, and is intended for in-vitro quantitative detection of NT-proBNP in human serum, plasma, and whole blood.

Despite the positive development of expanding its product line, Aiwei Biological Technology's new product is not expected to significantly impact Shandong Oriental Ocean Sci-Tech's 2025 performance. The company cautions investors that actual sales and future impact on profitability remain uncertain, subject to market expansion efforts and demand.